Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application crawled time : 08:20 save search
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Published: 2023-01-07 (Crawled : 08:20) - prnewswire.com
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
| Email alert
Add to watchlist
treatment fda disease alzheimer's application license approval
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Published: 2022-12-24 (Crawled : 08:20) - globenewswire.com
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
| Email alert
Add to watchlist
treatment fda application license review update
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.